Add-on to Chemoradiotherapy Doubles NSCLC Survival for Some Veterans

ANN ARBOR, MI – Median overall survival doubled for veterans with stage III non-small cell lung cancer who received chemoradiotherapy plus durvalumab, as compared to those receiving chemoradiotherapy alone, according to a new study. The authors note that the current standard of care for patients with unresectable stage III NSCLC is concurrent chemoradiotherapy followed by durvalumab maintenance, but veterans were not included in the trial establishing that protocol.

Male Veterans With Breast Cancer Fare Worse Than Females

ALBANY, NY – While survival rates for breast cancer generally have improved over the last decades, that is not true for at least one cohort of patients: men. In fact, increased mortality has been documented for male veterans with breast cancer, even after adjusting for age and other clinical factors. VA researchers tried to determine why.

Statins Reduce Some Lymphomas in Veterans With HIV

Statins appear to have immunomodulatory and anti-inflammatory effects and appear to reduce cancer risk. A new study sought to determine if that also is the case with HIV patients, who experience chronic inflammation and immune activation.

Prognosis Beginning to Improve for T-cell Lymphoma Patients

LONG BEACH, CA – Among hematological malignancies, T-cell lymphomas have an extremely poor prognosis. A new review suggested that might be changing with unusual paths to cure. An article in the Lancet Haematology pointed out that, over the last three decades, little...